This release is from the Corporate Headquarters of Boehringer Ingelheim and is intended for all international markets. This being the case, please be aware that there may be some differences between countries regarding specific medical information including licensed uses. Please take account of this when referring to the material.
References:
(1) Gazzard et al. Combined analysis of RESIST 96-week data: durability and efficacy of tipranavir/r in treatment-experienced patients; 8th International Congress on Drug Therapy in HIV Infection; 12-16 November 2006, Glasgow, UK. Poster P23.
Web site: http://www.boehringer-ingelheim.com/hiv
Judith von Gordon, CD Communications, Boehringer Ingelheim, +49-61-32-77-3582, or fax, +49-61-32-77-6601
